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A B S T R A C T
Cervical cancer remains a significant source of disease and death in Europe. However, we now have the means to pre-
vent virtually every case of cervical cancer through comprehensive, population-based, organised cervical cancer preven-
tion programmes that effectively integrate cervical screening with the new technologies and vaccines that are now available.
Given the potential health benefits of these programmes in reducing disease incidence and mortality, their establishment
is now an ethical imperative for all European countries.
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Introduction
Cervical cancer is the second most common cancer in
women worldwide and is the most common female can-
cer in the Caribbean, East / Central / Southern Africa and
in South-Central Asia. Globally, an estimated 471,000
women develop cervical cancer and 233,000 die from it
every year (estimate for 2000)1. The disease primarily af-
fects younger women with the majority of cases appear-
ing between the ages of 30 and 502, an age when many
are actively involved in their careers, caring for their
families or both and the impact on society as a whole is
therefore greatly increased.
Cervical cancer still remains an important public health
issue in Europe where it is the 7th most common cause of
cancer deaths in women1. Each year in Western Europe,
13,000 women develop cervical cancer and 6,000 women
die from this disease, while the situation in Eastern Eu-
rope is much worse with approximately 31,000 women
developing cervical cancer and about 17,000 dieing every
year3. This difference is largely due to the absence of ef-
fective cervical screening in Eastern Europe and the im-
plementation of properly organised prevention program-
mes would inevitably decrease the burden of this disease
in these countries.
Cervical Cancer Screening
Squamous cervical cancer is particularly amenable to
screening as it has a long pre-clinical phase and identifi-
able precursor lesions that, if detected early, can be
treated with high efficacy using simple outpatient proce-
dures. Indeed, effective organised cervical cancer screen-
ing programmes have been proven to reduce cervical can-
cer incidence and mortality by more than 80%4. However,
recent studies indicate that screening has limitations.
Data available from organised screening programmes
show that the initial declines in disease incidence seen
following the establishment of screening have now lev-
elled-off, indicating that the maximum effect of Pap
smear-based screening has been reached in these co-
untries4. Further, a meta-analysis of studies unaffected
by verification bias has shown that the pooled sensitivity
of the Pap smear was 77% (95% CI: 58% to 97%) when
using low-grade squamous intra-epithelial lesions (LSIL)
as the threshold to detect histologically confirmed cervical
intraepithelial neoplasia of grade 2 or worse (CIN2+)5.
Given these data, an enormous amount of research ef-
fort has gone into the evaluation of new technologies
such as liquid-based cytology and HPV testing, together
with HPV vaccination that offer the potential to make
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further progress in the battle against this disease. How-
ever, it must be remembered that achieving reductions in
the incidence and mortality of cervical cancer is entirely
dependent upon the effective operation of the entire
programme including primary prevention strategies such
as vaccination, screening, diagnosis and treatement of
pre-invasive or invasive disease. For these reasons, new
techologies with the potential to be deployed must also
be studied within the programme so the overall effect, in-
cluding all the benefits and drawbacks, can be properly
evaluated. Further, they should be evaluated within ran-
domised controlled trials in order to obtain un-biased
etimates of their effects.
The Human Papillomavirus
and Cervical Cancer
There is now an overwhelming body of evidence dem-
onstrating that persistent infection with certain types of
the Human papillomavirus (HPV) is the primary risk
factor for the development of cervical cancer and its pre-
cursor lesions6,7. More than 100 different HPV types
have been identified with approximately 40 of these in-
fecting the anogenital epithelium that have been classified
as either low-risk (LR) or high-risk (HR) for the develop-
ment of cervical cancer based upon their identification in
cervical tumour samples8. A recent analysis of 11 studies
has designated 15 anogenital HPV types as HR (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), with a
further 3 types designated as probably HR (26, 53 and
66)9 although some of these designations have been dis-
puted by others10.
This body of evidence is strong, consistent across dif-
ferent populations, and conclusively demonstrates that
HPV is a necessary (although not a sufficient) cause of
cervical cancer7,11. On the basis of these data, it is logical
to conclude that HPV testing could be a useful cervical
cancer screening tool12–18 and that vaccination against
HPV could be used for primary prevention of cervical
cancer.
HPV Testing for Primary Cervical
Cancer Screening
For primary screening, a number of research studies
(Table 1) have demonstrated that, compared to the Pap
smear, HPV testing has a higher sensitivity and higher
negative predictive value (NPV) for the detection of prev-
alent cervical cancer precursors, albeit with a lower spec-
ificity and lower positive predictive value (PPV)19–24.
However, it is important to note, these studies used a
cross-sectional design with double testing (cytology +
HPV testing) of all women and short-term follow-up by
colposcopy with biopsy for those having one or more posi-
tive screening tests. While this is appropriate to assess
the relative sensitivity of each test to detect prevalent
high-grade cervical intra-epithelial lesions (CIN2+), the
design is subject to verification bias and it does not ac-
count for the long duration of pre-cancerous stages and
the consequent increase in sensitivity that accompanies
repeated Pap smear testing (i.e. programme sensitivity).
Further, the high regressive potential of CIN2+ lesions
means that its increased detection may be accompanied
by the diagnosis and treatement of non-progressive le-
sions and the cross-sectional results therfore cannot be
used to study the impact of different screening strategies
on the incidence of invasive cancer25,26. As such, most ju-
risdictions have regarded these studies as insufficient to
merit the introduction of HPV testing for primary scre-
ening, while an international expert group convened by
the International Agency for Research on Cancer (IARC)
has concluded that HPV testing has at least the same
cross-sectional sensitivity as the Pap smear and that it
could be used within organised screening programmes,
either alone or in combination with the Pap smear, once
rigorous evaluation of effectiveness and efficacy have
been completed4. Such studies are underway in Europe
where a number of researchers have established large-
-scale randomised controlled trials (RCTs) of HPV test-
ing for primary screening which follow-up women for at
least one screening round, and the Finnish Cancer Regis-
try has initiated a randomised public health implementa-
tion evaluation of HPV screening27–32 (Table 2).
Importantly, some of these RCTs have moved to the
evaluation of HPV testing as a single primary screening
test followed by cytology for the triage of women having a
positive test on the basis that:
– screening would be undertaken with the test having
higher sensitivity and triage undertaken with the test
having higher specificity, in compliance with accepted
principles of screening, and as is already the case with
syphilis and HIV screening,
– it would maximise specificity and PPV while achieving
95–100% of the sensitivity and NPV of the combined
HPV/cytology primary test. This would provide the
same level of safety but with improved cost-effective-
ness by minimising the number of women with false
positive results that need to be followed-up,
– it would allow 85–90% of women to return immedi-
ately to routine recall without incurring the cost of cy-
tology, which would be reserved only for the triage of
the remaining 10–15% of women with a positive HPV
test,
– the high-volume testing of screening samples would be
undertaken with a non-subjective test that can be au-
tomated, while the subjective, labour-intensive test
would be restricted to high-risk samples only, so they
could be screened more intensively because of the re-
duced number that need to be processed.
The interim results of these trials confirm the earlier
studies with HPV testing (either alone or in combination
with cytology) having a higher sensitivity and lower spec-
ificity than cytology alone for the detection of CIN2+.
However, those studies reporting the performance of
HPV testing as a single primary screening test with cy-
tology triage indicate that this HPV screening algorithm
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also has a higher sensitivity than cytology alone but now
with a specificity that is at least equivalent to cytology. In
the Finnish trial, HPV testing with cytology triage de-
tected 1.45 times as much CIN2+ compared to cytology
alone, while the specificities were not significantly differ-
ent at 98.9% (95% CI: 98.6–99.2) and 99.3 (95% CI:
99.0–99.5), respectively27. Similar results were reported
by Bulkmans et. al in the preliminary prospective results
from the POBASCAM trial in which indicate that HPV
testing followed by cytology triage compared to cytology
alone can be more sensitive (92.9 vs 64.3% respectively;
p=0.065) and more specific (96.8 vs 95.1% respectively;
p= 0.05)29. While the differences in sensitivity, NPV
(99.96 vs 99.78% respectively; p=0.098) and PPV (14.6
P. Davies et al.: Cervical Cancer Prevention in Europe, Coll. Antropol. 31 (2007) Suppl. 2: 11–16
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TABLE 1
SENSITIVITY AND SPECIFICITY OF HPV TESTING COMPARED TO CERVICAL CYTOLOGY FOR THE DETECTION







Sen Spec Sen Spec Sen Spec
Cuzick et al.19 United Kingdom: n = 1,703
Conventional Pap Smear, HC2,  ³ 35 years
95 95 79 99 NA NA
Schiffman et al.20 Costa Rica: n = 1,119
Conventional Pap Smear, HC2,  ³ 18 years
88 89 78 94 NA NA
Ratnam et al.21 Canada: n = 2,098, 69% HC1/31% HC2,  18–69













Clavel et al.22 France: n = 5,651
LBC, HC2,  ³ 15 years
100 86 88 93 NA NA
Petry et al.23 Germany: n = 8,468
Conventional Pap Smear, HC2,  ³ 30 years
98 96 44 98 100 94
Cuzick et al.24 United Kingdom: n = 10,358
Conventional Pap Smear, HC2,  ³ 30 years
HC2 using an elevated threshold (³ 2pg)













ASC-US — Atypical Squamous Cells – Undetermined Significance, CIN – Cervical Intraepithelial Neoplasia, Sen — Sensitivity, Spec
— Specificity; HC2 — Hybrid Capture 2 HPV test and HC1 — Hybrid Capture 1 HPV test (Digene Inc. Gaithersburg, MA), LBC —
Liquid Based Cytology, * Sensitivity of HC1 was suboptimal and would have contributed to the difference seen between HPV testing
alone and the combination of HPV testing with Pap
TABLE 2










Finland 200,000 25–65 HC2 Conventional
Pap smear
Cumulative incidence of CIN2,
CIN3 and cancer after
initial screening







at the exit screen






confirmed CIN3+ found at any
time during the trial from
recruitment to exit screen
ARTISTIC31 United Kingdom 25,000 20–64 HC2 LBC Comparative prevalence of
histologically confirmed CIN3+
at the exit screen





from the recruitment screen up
to and including the exit screen
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vs 7.3% respectively; p=0.085) are not significant, it
must be remembered that these are only the preliminary
results on 2,810 women from a total of over 44,000
women that were recruited to the trial.
Taken together, these results indicate that HPV test-
ing, if used as a primary screening test followed by cytol-
ogy for the triage of women testing HPV positive, has the
potential to provide improved sensitivity for the detec-
tion of clinically relevant disease without decreasing
specificity or otherwise adversely affecting the efficacy of
screening programmes.
Vaccination Against HPV for Primary
Prevention of Cervical Cancer
A number of studies have now been conducted on the
two first generation prophylactic HPV vaccines33–38. Both
vaccines target HR-HPV types 16 & 18 (which are to-
gether responsible for over 70% of cervical cancers world-
wide), while one (GARDASIL®, Merck and Co.) also in-
cludes types 6 and 11 which are non-oncogenic but still
responsible for a substantial proportion of lower-grade
cervical disease and the other (CERVARIX™, Glaxo-
SmithKline) has demonstrated to provide a degree of
cross-reaction to HPV types 31 & 45 (which are the next
most common oncogenic HPV types after 16 & 18)38. The
result of the phase IIb and III trials have shown these
vaccines to be safe, well tolerated and highly immu-
nogenic. Further, both vaccines have been shown to offer
HPV naive women high levels of protection against HPV
infection with the HPV types contained in the vaccine as
well as their resulting cervical lesions33–38. However, the
GARDASIL licensing submissions filed with both the US
Food and Drug Administration and the European Medi-
cines Agency included data to show there was no clear ev-
idence of protection from disease caused by HPV types
which subjects were DNA positive and/or seropositive for
at the time of vaccination39,40. Further data were pre-
sented to show that in the general public where a propor-
tion of women will have prior or current HPV infections,
GARDASIL can be expected to reduce the overall rate of
CIN2/3 or adinocarcinoma in situ caused by vaccine or
non-vaccine types by 12.2%39.
The results of these trials have now led to the li-
censure of one of the vaccines in many countries with the
second expected to follow shortly and it is anticipated
that these vaccines will play a very important role in the
prevention of cervical cancer going forward. However,
the availability of these vaccines raises several imple-
mentation issues that must be addressed if the vaccines
are to achieve their full potential in Europe where cervi-
cal cancer screening is already widespread and substan-
tial efforts are underway to ensure the uniform imple-
mentation of properly organised cervical cancer screening
programmes. In Europe, the enormous potential of HPV
vaccination must be considered together with its limita-
tions which are chiefly 1) its high cost (currently around
450 per person in France), 2) that the first-generation
vaccines do not protect against all HR HPV types, and 3)
inability to protect women who are already infected with
HPV types 16 and 18. In addition, an important question
remains about whether HPV vaccination will provide
any supplemental protection against the development of
cervical cancer in women who have been exposed to HPV
16 or 18 but subsequently mounted their own effective
immune response and cleared the virus. This is a particu-
larly important question for public health programmes
where the cost for the vaccine must be taken from finite
healthcare budgets and which will therefore lead to a
diminution in other services. Clearly, there is an ethical
concern about the implementation of vaccination pro-
grammes for women who may derive little or no addi-
tional benefit over that provided by their own immune
system when the money must come from other program-
mes with clear and proven health benefits.
Under these conditions, there is little dispute that the
vaccination of girls before the commencement of sexual
activities is not only a public health priority but an ethi-
cal imperative. However, the use of vaccination in older
girls and women will yield diminishing public health re-
turns as the proportion of women exposed to HPV 16 &
18 increases, and this needs to be balanced against the
clearly established protective effect of cervical screening
in these populations. Unfortunately, it is not possible to
have a single formula and each country must undertake
its own cost-benefit analysis to establish the appropriate
balance depending on their national priorities, health-
care budgets and the status of existing resources such as
screening programmes. But what is clear that all Euro-
pean countries now need to implement comprehensive
cervical cancer prevention programmes which integrate
cervical screening together with HPV vaccination as it is
the combination of these that will offer the most effective
long-term protection against cervical cancer. Further,
these new measures of cervical cancer prevention must
be offered within population-based organised prevention
programmes to ensure that the protection is equitably
available to all women in the population.
The Effective Integration of Technologies
for the Prevention of Cervical Cancer
Although the Pap smear has been the mainstay of cer-
vical cancer prevention for more than 50 years, it now
must be recognised that the ongoing uptake of HPV vac-
cination against HPV 16 & 18 will have a progressively
detrimental effect on cytology based screening. Evalua-
tions of the prevalence of HPV 16 & 18 among women
with abnormal cytology indicate that ASC-US, LSIL and
HSIL rates could be reduced by as much as 30%, 36% and
55% respectively in a population that was fully vacci-
nated with a vaccine having 100% efficacy41–43. If HPV 6
and 11 are also included, ASC-US, LSIL and HSIL could
eventually be reduced by a total of 40%, 46% and 60%
respectively41–43. Here, it is important to note that the re-
ductions are likely to be greater for HSIL than for
ASCUS or LSIL. Therefore, vaccination will both reduce
the overall prevalence of cytological abnormalities and
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shift the balance to the lower grades which have a lower
PPV. These characteristics mean that vaccination will in-
evitably lead to a substantial deterioration in the efficacy
of cytology-based screening because:
1) A decrease in disease prevalence will produce a di-
rect and simultaneous decrease in the PPV of screening.
Even with current disease rates in adequately screened
populations, the PPV of cervical cytology ranges from
only 10 to 30% for the detection of CIN2+ in well
screened populations19–24 a situation that is only toler-
ated because of the seriousness of the disease that cervi-
cal screening prevents. However, reductions in disease
rates subsequent to widespread vaccination, together
with the shift to the lower-grades of cytological abnor-
malities, will further reduce the PPV of cytology-based
screening programmes, eventually to a point where the
stress, morbidity and costs involved in the follow-up of
these false-positive women may no longer be either ethi-
cally or financially justifiable relative to the yield of true
disease.
2) Reductions in disease rates would also mean that
cytology screeners would have less exposure to cytologi-
cal abnormalities during the course of their working day
with two possible outcomes. First, regular exposure to
cytological abnormalities is necessary for the mainte-
nance of cytology screening skills. Therefore, reductions
in disease rates could be accompanied by a simultaneous
reduction in the cytology screeners’ ability to recognise
these abnormalities and a reduction in the sensitivity of
the screening program. Second, a reduction in the num-
ber of true abnormalities could lead cytology screeners to
compensate by over-classifying inflammatory changes or
reactive atypias leading to further decreases in specific-
ity and PPV of the screening programme.
Although these changes will only be seen with the
progressive implementation of HPV vaccination and the
gradual expansion of the vaccinated cohort, it is nonethe-
less essential for screening programmes to make plans
for the changes that will be required to maintain proper
levels of protection against cervical cancer. One way this
could be achieved is by stratifying the population to be
screened according to their risk and then applying cytol-
ogy based screening only to the subpopulation of women
that is at increased risk of having clinically relevant cer-
vical disease, i.e. those women who are HPV positive. On
this basis, the uptake of HPV vaccination will necessitate
a shift to HPV testing for primary screening together with
cytology for the triage of women with a positive result in
order to maintain the efficacy of screening in an environ-
ment with a reduced prevalence of cervical disease.
Conclusions
In Europe, cervical cancer remains a significant so-
urce of disease and death although we now have the
means to prevent virtually every case through compre-
hensive cervical cancer prevention programmes. How-
ever, if we are to achieve this goal, it is essential that
these prevention programmes effectively integrate cervi-
cal screening together with the new technologies and
vaccines to ensure that the optimal protection is afforded
to all age groups. In addition, they must be popula-
tion-based to ensure that the protection is equitably
available to all women and they are run in the most
cost-effective fashion. The science has been done and the
tools are now available to effectively prevent cervical
cancer in Europe. What we now need is the political will
to make this a reality.
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BUDU]NOST PREVENCIJE RAKA VRATA MATERNICE U EUROPI
S A @ E T A K
Rak vrata maternice je i dalje zna~ajan izvor bolesti i smrti u Europi. Me|utim, danas postoji na~in prevencije
gotovo svakog slu~aja raka vrata maternice kroz opse`ne organizirane programe prevencije, temeljene na populaciji,
koji u~inkovito spajaju probir za rak vrata maternice s novim metodama koje su danas dostupne. Pridaju}i zasluge u
smislu mogu}ih zdravstvenih dobrobiti ovom programu u smanjenju stope pojavnosti i smrtnosti od ove bolesti, njegovo
uspostavljanje je danas eti~ki imperativ za sve europske zemlje.
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